|
|
|
Volumn 20, Issue 14 Suppl 10, 2006, Pages 21-28
|
|
Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR;
MONOCLONAL ANTIBODY;
PANITUMUMAB;
VASCULOTROPIN A;
CLINICAL TRIAL;
COLORECTAL TUMOR;
DRUG ANTAGONISM;
DRUG DELIVERY SYSTEM;
HUMAN;
IMMUNOLOGY;
METHODOLOGY;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
COLORECTAL NEOPLASMS;
DRUG DELIVERY SYSTEMS;
HUMANS;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 34047219240
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (32)
|
|
References (27)
|
